

cDNA microarrays detect activation of a myogenic transcription program by the *PAX3-FKHR* fusion oncogene

Javed Khan*, Michael L. Bittner*, Lao H. Saal*, Ulrike Teichmann†, David O. Azorsa*, Gerald C. Gooden*, William J. Pavan†, Jeffrey M. Trent*, and Paul S. Meltzer**

*Cancer Genetics Branch and †Genetic Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892

Communicated by Francis S. Collins, National Institutes of Health, Bethesda, MD, September 22, 1999 (received for review July 23, 1999)

Alveolar rhabdomyosarcoma is an aggressive pediatric cancer of striated muscle characterized in 60% of cases by a t(2;13)(q35;q14). This results in the fusion of *PAX3*, a developmental transcription factor required for limb myogenesis, with *FKHR*, a member of the forkhead family of transcription factors. The resultant *PAX3-FKHR* gene possesses transforming properties; however, the effects of this chimeric oncogene on gene expression are largely unknown. To investigate the actions of these transcription factors, both *Pax3* and *PAX3-FKHR* were introduced into NIH 3T3 cells, and the resultant gene expression changes were analyzed with a murine cDNA microarray containing 2,225 elements. We found that *PAX3-FKHR* but not *PAX3* activated a myogenic transcription program including the induction of transcription factors *MyoD*, *Myogenin*, *Six1*, and *Slug* as well as a battery of genes involved in several aspects of muscle function. Notable among this group were the growth factor gene *Igf2* and its binding protein *Igfbp5*. Relevance of this model was suggested by verification that three of these genes (*IGFBP5*, *HSIX1*, and *Slug*) were also expressed in alveolar rhabdomyosarcoma cell lines. This study utilizes cDNA microarrays to elucidate the pattern of gene expression induced by an oncogenic transcription factor and demonstrates the profound myogenic properties of *PAX3-FKHR* in NIH 3T3 cells.

Tumor-specific chromosome translocations that encode chimeric transcription factors are thought to exert their oncogenic effects through the dysregulation of gene expression (1). New technologies for large-scale expression analysis, such as cDNA microarrays, provide the opportunity to observe the broad effects of oncogenic transcription factors on gene expression and potentially elucidate their role in oncogenesis. The *PAX3-FKHR* chimera found in alveolar rhabdomyosarcoma (ARMS) fuses the DNA binding domain of *PAX3* with the trans-activation domain of *FKHR* (2, 3), thereby retaining the DNA binding specificity of *PAX3* and potentially acting in ARMS to increase expression of genes containing *PAX3* binding sites. Although *PAX3-FKHR* binds less avidly to its targets than *PAX3*, it is a much stronger transactivator than *PAX3* (4, 5). In murine embryogenesis, *PAX3* expression is temporally regulated to induce both myogenesis and neural crest development. *PAX3* is necessary for limb muscle development as homozygous *Splotch* mice, which have *PAX3* mutations, do not develop limb muscles and fail to express myogenic basic helix-loop-helix factors in these regions (6). *PAX3* expression is found in the muscle precursor cells of the lateral dermomyotome; the cells then migrate to the limb buds, where *PAX3* expression is later repressed upon the formation of the limb musculature. In ARMS, the chimeric *PAX3-FKHR* gene is often highly expressed (2, 7–9), and continuous expression of this gene may inhibit terminal differentiation and maintain the cells in a primitive myoblastic state that retains abnormal proliferative potential. In accord with this model, Epstein *et al.* (10) have demonstrated that expression of *PAX3* or *PAX3-FKHR* can prevent terminal myogenic differentiation in C2C12 myoblasts. Additionally,

PAX3-FKHR is able to transform chicken fibroblasts and NIH 3T3 cells (11, 12). Presumably, all of these effects result from alterations in the expression of *PAX3* target genes by *PAX3-FKHR*.

To observe the effects of either *Pax3* or *PAX3-FKHR* on gene expression, we introduced these genes into NIH 3T3 cells by retroviral transduction and monitored their effect on global gene expression by using a murine cDNA microarray. Introduction of *PAX3-FKHR* resulted in increased expression of several genes including the transcription factors *Myogenin*, *MyoD*, and *Six1*, as well as numerous other muscle-specific genes. In sharp contrast, *PAX3* failed to induce these genes but repressed several genes, some of which were also down-regulated by *PAX3-FKHR*. The relevance of these changes to ARMS was confirmed by Northern blot analysis of ARMS cell lines. Our observations are consistent with a model in which occurrence of the t(2;13)(q35;q14) in a tumor progenitor cell leads to a persistent myoblastic state followed by secondary genetic events leading eventually to ARMS.

Materials and Methods

Retroviral Transduction and Cell Cultures. NIH 3T3 cells were grown in 90% DMEM and 10% FBS. The *PAX3-FKHR* and *Pax3* cDNAs (the kind gift of Lee Helman, National Cancer Institute) were subcloned between the *HpaI* and *ClaI* sites of the retroviral vector pLNCX (13) and were sequenced to verify encoding of the correct proteins. Virus was generated from these plasmids and the empty vector by transient transfection of BING cells and was used to infect NIH 3T3 cells as per published protocols (14). The cells were incubated with viral supernatant for 6 hours and were split 48 hours later in medium containing LD₁₀₀ levels of G418 (600 µg/ml). After 2 weeks of selection in this medium, polyclonal populations of G418 resistant cells (designated *PAX3-C*, containing *Pax3* gene; *PF-C*, containing *PAX3-FKHR*; and *NIL-C*, containing empty vector) were derived. In addition, individual clones were derived by splitting cells at >1:100 dilution and picking individual colonies for expansion (*PAX3-1*, *PF-1*, and *PF-3*). Human ARMS cell lines (*RH3*, *RH4*, *RH5*, *RH28*, and *RH30*) containing the *PAX3-FKHR* gene and a sarcoma (*A204*) were cultured as described (15). All cell lines were harvested at 80–85% confluency.

Northern Blot Analysis. RNA was extracted by using TRIzol (Life Technologies, Rockville, MD) followed by single round mRNA extraction (Amersham Pharmacia) for the human cell lines and

Abbreviation: ARMS, alveolar rhabdomyosarcoma.

*To whom reprint requests should be addressed at: National Human Genome Research Institute, National Institutes of Health, Building 49, Room 4A10, 49 Convent Drive, Bethesda, MD 20892-4470. E-mail: pmeltzer@nhgri.nih.gov.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

RNeasy (Qiagen, Chatsworth, CA) for the NIH 3T3 cells. mRNA (6 μ g) for human and 15 μ g of total RNA for murine lines were size fractionated, were transferred to nylon membranes, and were hybridized according to standard protocols. The 32 P labeled probes were generated from DNA either by PCR (5' *Pax3*, Myogenin, *MyoD*, *Igf2*, *HSIX1*, *IGF2*, *Pdgfra*), or restriction digest of insert (*IGFBP5*, *Slug*, *MERTK*) from sequence verified IMAGE consortium clones (Research Genetics, Huntsville, AL), or reverse transcription-PCR from RNA from clone PF-1 (*Six1*, *Igfbp5*, *Slug*, *c-Met*). Human and murine *GAPDH* probes were purchased from CLONTECH.

Western Blot Analysis. Detergent lysates containing 60 μ g of total protein from the cell lines NIL-C, PF-C, PF-1, PF-3, PAX3-C, and PAX3-1 were separated by using SDS/PAGE, were transferred to nylon membranes (Immobilon-P, Millipore), and were probed with the appropriate antibodies using standard protocols. Rabbit anti-PAX3 polyclonal antisera was a generous gift from Frank Rauscher III (Wistar Institute). Rabbit anti-tubulin IgG was from ICN. Rabbit anti-Myogenin and MyoD were from Santa Cruz Biotechnology, and horseradish peroxidase-conjugated goat anti-rabbit H&L was from Jackson ImmunoResearch.

Reporter Assays. The PAX3 reporter plasmid, plucTKCD-19 (kindly provided by Frank Rauscher III, Wistar Institute), contains six e5 sequences adjacent to a minimal thymidine kinase promoter region. Transfection efficiency was controlled by using the plasmid pCMV-RL. plucTKCD-19 (3 μ g) was co-transfected with 100 ng of the pCMV-RL into 5×10^5 cells for the lines NIL-C, PF-C, and PAX3-C, using lipofectamine (Life Technologies) for 4 hours. The cells were harvested at 48 hours and were analyzed for Renilla and firefly luciferase activity by using a dual luciferase kit (Promega).

cDNA Microarrays. The cDNA microarray arrays consisted of 2,225 elements that included 2,092 known mouse genes that were identified by sequence comparison of the murine EST database with 3,282 mouse UniGene entries and obtained from Research Genetics. The remainder of the printed genes were conventional cDNA clones representing mouse developmental genes added to expand the utility of these arrays for developmental studies. PCR products from these clones were prepared and printed onto glass slides according to previously described protocols (16, 17). RNA was extracted from cells with two rounds of purification with the RNeasy kit, followed by TRIzol purification. Fluorescently labeled cDNA with either Cy3 or Cy5 (Amersham Pharmacia) was synthesized from 100–200 μ g of total RNA by oligo(dT)-primed polymerization using SuperScript II reverse transcriptase (Life Technologies) as described (15). For each hybridization we used the same reference RNA, from NIL-C, labeled with one of the two fluorochromes, Cy3 or Cy5, and the test line (NIH 3T3, PF-C, PF-1, PF-3, PAX3-C, PAX3-1) with the other.

Imaging and Image Analysis. Fluorescence intensities at the immobilized targets were measured by using a custom-designed laser confocal microscope as reported (18) with intensity data integrated over 15-micron square pixels and recorded at 16 bits. Image analysis was performed by using DEARRAY software as described (19). All of the data, including fluorescent intensities of both channels and calibrated intensity ratios, were entered into a FileMaker Pro database. Results are available on the internet (<http://www.nhgri.nih.gov/DIR/LCG/15K/HTML/>).

Results

Retroviral Transfer of *Pax3* and *PAX3-FKHR* into NIH 3T3 Cells. The expression levels of *Pax3* and *PAX3-FKHR* in the pooled population and individual clones transduced with these genes were




Fig. 1. (A) Northern blot analysis confirms expression of *PAX3-FKHR* in the lines PF-C, PF-1, and PF-3 and *Pax3* in PAX3-C and PAX3-1. (B) Western blot analysis confirms comparable levels of these proteins in accord with the Northern blot data. (C) Relative luciferase activity of *PAX3-FKHR* (in PF-C) showing $\approx 6\times$ the transcriptional activity of *Pax3* (in PAX3-C), as described (4). The assay was performed according to published protocols (42) using the *Pax3* reporter plasmid plucTKCD19.

comparable as determined by both Northern blot and Western blot analysis (Fig. 1 A and B). The activity of the transduced genes was confirmed by transient transfection assays using a PAX3 responsive reporter. As expected from published reports (4), we observed that *PAX3-FKHR* was ≈ 6 -fold more potent than *PAX3* in this assay (Fig. 1C).

Identification of Genes Responsive to *Pax3* and *PAX3-FKHR* Transduction. To determine the downstream effects of PAX3 and PAX3-FKHR, we performed cDNA microarray gene expression analysis on the pooled populations (PAX3-C and PF-C), their clonal derivatives (PAX3-1, PF-1 and PF-3), and the parental NIH 3T3 cells using 2,225 element murine cDNA microarrays. In each experiment, we used the empty vector transduced line (NIL-C) as the control. Fig. 2 illustrates corresponding portions of arrays in which NIL-C (labeled green) is compared with NIH 3T3 (red) and to the pooled populations PAX3-C and PF-C (both red). Expression levels of several genes were altered as a result of these manipulations in the experimental cells. To examine these effects, we entered the results into a database that was queried to identify the genes induced or repressed at the 99% confidence level as a result of *PAX3-FKHR* transduction in PF-C, PF-1, and PF-3. For this initial analysis, we used highly stringent filter, which included only genes with fluorescence signals $\geq 5,000$ (on a scale of 0–65,535 fluorescent units) for at least one of the two channels. This process identified 11 genes that were induced in all three of *PAX3-FKHR*-transduced lines and 4 genes that were repressed. Fig. 3 summarizes the result of this inquiry. We confirmed that these changes were not attributable to the retrovirus or G418 treatment by comparing the gene expression




Fig. 2. Representative microarray hybridization of transduced lines. For each experiment, we used the same reference target prepared from cells transduced with empty vector (designated NIL-C). The pseudocolored images represent portions of a microarray with reference target, NIL-C, in green and parental NIH 3T3, PAX3-C, and PF-C in red. Up-regulation of several genes of interest by PAX3-FKHR are boxed (1, Fast skeletal troponin C; 2, *Igfbp5*; 3, Myogenin; 4, *Six1*; 5, Cardiac troponin T; 6, *Ig2*).

of the parent NIH 3T3 cells to the NIL-C population. None of the 11 induced genes were induced to comparable levels by PAX3 in either the pooled population (PAX3-C) or in the clonal isolate (PAX3-1). Remarkably, of the 11 induced genes, 10 were muscle-related. These included *Igfbp5* (>100-fold induction), Troponin T (49 \times), Troponin I (42 \times), Complement factor H (37 \times), Troponin C (22 \times), Myogenin (14 \times), *Igf2* (8 \times), *Six1* (5 \times), Myosin light chain 4 (4 \times), and *Slug* (3 \times). The final gene identified in this initial screen *Mertk* (6.8 \times induced) is an embryonic receptor tyrosine kinase protooncogene (20). Expression of several of these genes, including *IGFBP5* and *HSIX1*, has not previously been reported in ARMS. At this level of stringency, there were also four genes repressed by PAX3-FKHR transduction (Fig. 3), including *Pdgfra* (0.6-fold), *Fisp12* (0.4), *Pmx1* (0.5), and *Daf* (0.5). Interestingly, *Pax3* transduction also caused repression of three of these genes (*Daf*, *Pmx1*, and *Pdgfra*).

We then widened the search for genes induced by PAX3-FKHR transduction by using less stringent filters. We queried the database for all PAX3-FKHR-induced genes with $\geq 50\%$ induction (ratio ≥ 1.5) in at least two of the three PAX3-FKHR-transduced cell lines by using an intensity filter of $\geq 1,400$ for either channel. This identified 111 genes, of which a large proportion (28/111) were muscle related (Table 1). These 28 included genes involved in widely varied aspects of muscle function, including transcriptional regulation, signal transduction, contractility, energy metabolism, and synaptic transmission. Only one of these genes (Na^+/H^+ -exchanger regulatory factor) was induced by *Pax3* transduction in PAX3-C and PAX3-1. This observation suggests that PAX3-FKHR can function as a master regulator of muscle gene expression in NIH 3T3 cells.

Confirmation of Gene Induction. To verify the microarray results, we performed Northern blot hybridizations on RNA extracted from the transduced cells using probes for selected genes (Fig.




Fig. 3. (A) Eleven genes induced in PF-C, PF-1, and PF-3. The intensity ratio (log₁₀ scale) is plotted against the 11 genes induced (at the 99% confidence level in each individual experiment) for all five microarray hybridizations. When the intensity values for both red and green channels for a probe/spot were $< 1,400$, then the ratio of gene expression cannot be determined with precision, and the ratio value is plotted as 1. Boxed numbers correspond to genes from Fig. 2. (B) Four genes down-regulated by PAX3-FKHR, of which three (*Daf*, *Pmx1*, and *Pdgfra*) were also repressed by PAX3. A stringent filter, including only those genes with fluorescence $\geq 5,000$ for either red or green channels, was applied for this analysis.

44). Expression of *Six1* in the NIL-C population (and NIH 3T3) (data not shown) was low, and induction was confirmed in the PF-C, PF-1, and PF-3 clones and not in the *Pax3*-transduced cells. Similarly, expression of the myogenic transcription factor Myogenin was undetectable in the control cells and was markedly induced after PAX3-FKHR introduction, particularly in PF-1. Because Myogenin is postulated to be downstream of *MyoD* and *Myf5* (neither gene was represented on our cDNA microarray), we performed reverse transcription-PCR on PF-1 confirming the expression of *MyoD* but not *Myf5* (data not shown). Northern blot analysis using the *MyoD* reverse transcription-PCR product as probe demonstrated (Fig. 4A) *MyoD* expression in all of the PAX3-FKHR but not in the control or *Pax3* transduced clones. Myogenin expression was confirmed at the protein level by Western analysis (Fig. 4B), and expression of both Myogenin and MYOD also was observed by immunohistochemistry (data not shown). The expression and induction of *Igfbp5* followed the same pattern, with highest expression found in PF-1. Interestingly PF-1 also had high levels of induction of *Igf2*, although *Igf2* expression was detected at moderate levels in the NIL-C control cells. Similarly, *Slug* had a basal level of expression in the control cells but was further increased in the

Table 1. Muscle-related genes induced by PAX3-FKHR transduction

| | Gene symbol | PF-C | PF-1 | PF-3 | PAX3-C | PAX3-1 |
|---|---------------|------|------|------|--------|--------|
| Transcription factors | | | | | | |
| Myogenin | <i>Myog</i> | 14 | 58.9 | 22.3 | NS | NS |
| Six1 | <i>Six1</i> | 5.3 | 4.7 | 3.5 | 0.7 | 0.8 |
| Slug | <i>Slug</i> | 2.6 | 2.4 | 2.5 | 0.8 | 0.9 |
| Signal transduction/growth factors | | | | | | |
| Insulin-like growth factor binding protein 5 | <i>Igfbp5</i> | >100 | >100 | 91.2 | NS | NS |
| Insulin-like growth factor 2 | <i>Igf2</i> | 7.9 | 17.6 | 3.1 | 0.3 | NS |
| Transforming growth factor β 2 | <i>Tgfb2</i> | 2.8 | 3.8 | 0.9 | NS | NS |
| Contractility/Cell structure | | | | | | |
| Cardiac troponin T | <i>Tnnt2</i> | 49.1 | 65.9 | 23.9 | NS | NS |
| Fast skeletal muscle troponin 1 | <i>Tnni2</i> | 41.8 | >100 | 34.3 | NS | NS |
| Fast skeletal troponin C | <i>Tnnc2</i> | 22.4 | 81.0 | 27.7 | NS | NS |
| Skeletal muscle myosin light chain 1 isoform | <i>Myl1</i> | 16.9 | 80.4 | 0.7 | NS | NS |
| Perinatal skeletal myosin heavy chain | <i>Myh8</i> | 10.2 | 76.1 | 7.9 | NS | NS |
| Atrial/fetal myosin alkali light chain | <i>Myl4</i> | 4.3 | 60.7 | 11.7 | NS | NS |
| Alpha cardiac actin | <i>Actc</i> | 2.9 | 7.0 | 2.1 | 1.9 | 1.3 |
| Beta-tubulin gene M- β -2 | <i>Tubb2</i> | 1.8 | 2.1 | 2.5 | 1.3 | 0.7 |
| Myosin binding protein H | <i>Mybph</i> | 1.8 | 7.8 | 1.8 | NS | NS |
| Skeletal muscle α actin | <i>Acta1</i> | 1.8 | 7.4 | 1.4 | NS | NS |
| Tropomyosin isoform 2 | <i>Tmp2</i> | 1.6 | 4.2 | 0.8 | 0.8 | 1.2 |
| Energy metabolism | | | | | | |
| Creatinine kinase M chain | <i>CkM</i> | 5.2 | 27.6 | 8.5 | NS | NS |
| Acyl-CoA dehydrogenase short-chain | <i>Acads</i> | 1.5 | 1.5 | 1.5 | 0.6 | 0.9 |
| Fructose-biphosphate aldolase A | <i>AldoA</i> | 1.2 | 2.0 | 2.1 | 1.4 | 2.0 |
| Synaptic transmission/electrochemical function | | | | | | |
| Acetylcholine receptor, γ -chain | <i>Achrg</i> | 17.5 | 68.8 | NS | NS | NS |
| Acetylcholine receptor α -subunit | <i>Achra</i> | NS | 17.3 | 7.9 | NS | NS |
| Ryanodine receptor, type 1 | <i>Ryr1</i> | 3.4 | 19.8 | NS | NS | NS |
| Na ⁺ /H ⁺ -exchanger regulatory factor | <i>Nherf</i> | 2.9 | 3.4 | 2.7 | 2.1 | 3.2 |
| Na ⁺ /K ⁺ -transporting ATPase β -chain | <i>Atp1b1</i> | 2.1 | 1.8 | 3.4 | 0.8 | 0.6 |
| Other | | | | | | |
| Complement factor H | <i>Hf1</i> | 37.0 | 18.9 | 87.3 | NS | NS |
| H19 | <i>H19</i> | 18.2 | 36.5 | NS | NS | NS |
| Clusterin | <i>Clu</i> | 1.6 | 0.3 | 2.0 | NS | NS |

Listed are genes with $\geq 50\%$ induction (ratio of ≥ 1.5) by PAX3-FKHR transduction in at least two of the PF-C, PF-1, and PF-3 clones. A filter was used to exclude all spots with the maximum intensity $< 1,400$ (on a scale of 0–65,535 fluorescent units) for either fluorochrome (designated NS). Of the 111 genes retrieved by this enquiry, 28 were found to be muscle-related as determined by a search of Medline database. Shown here are the gene name, gene symbol, functional categories, and the induction ratio for each of the experiments.

PAX3-FKHR transduced cells. *c-Met* has been implicated as a PAX3-FKHR target (21). In our system the basal level of *c-Met* expression was high in the control cells, and we did not observe induction of this gene by either PAX3-FKHR or PAX3. We also investigated three of the repressed genes by Northern blot hybridization, confirming repression of *Pdgfra* (Fig. 4A), *Fisp12*, and *Pmx1* (data not shown).

Expressions of Genes Predicted from the NIH 3T3 Model in ARMS Cell Lines. To test whether these induced genes were also expressed in ARMS as predicted by our model system, we performed Northern blot analysis (Fig. 4C) on five ARMS cell lines (RH3, RH4, RH4, RH28, and RH 30) and compared them with normal muscle and a sarcoma (A204). Several of these genes (HSIX1, *IGFBP5*, *Slug*, and *MERTK*) have not previously been reported as expressed in ARMS. We confirmed the expression of the 7.3-kilobase PAX3-FKHR gene in all five ARMS and not in A204 or normal muscle. HSIX1 was expressed at high levels in all five ARMS and in A204 and, in accord with published reports (22), at low levels in normal muscle. As expected, expression of *MYOG* (23) and *IGF2* (24) was high in all five ARMS but not A204. The expression of *IGFBP5*, not previously described in ARMS, evident in all five of the cell lines, was particularly high in RH5. In addition, *Slug* was expressed in all five ARMS and in

A204. *MERTK* levels were relatively high in A204, and lower levels of expression were detected in RH3, RH4, and RH30.

Discussion

Induction of a Myogenic Transcription Program by PAX3-FKHR. In this study, we have monitored the downstream effects of both PAX3 and PAX3-FKHR on NIH 3T3 cells with cDNA microarrays. We observed the remarkable ability of PAX3-FKHR to induce a myogenic transcription program, which includes induction of two important myogenic basic helix-loop-helix factors, Myogenin and *MyoD*, which are also expressed in ARMS (23). In addition, we observed induction of genes that represent several other key aspects of muscle function, including growth, energy metabolism, and contractility (Table 1). The observed induction of many of the genes associated with muscle differentiation is most likely a consequence of Myogenin and *MyoD* expression. Of interest, *Myl4*, a fetal muscle gene that is absent from adult muscle (25) was also identified in our previous study of ARMS using human cDNA microarrays in which we found *MYL4* expression in all seven ARMS cell lines tested (15).

In addition to induction of genes previously associated with ARMS, we also observed induction by PAX3-FKHR of other potentially significant genes such as *Six1*, *Slug*, and *Igfbp5*, which has not previously related to the PAX3 pathway. *Six1* is a homeobox gene, the murine ortholog of the *Drosophila* “sine




Fig. 4. Northern blot analysis confirms array data. (A) Induction of *Six1*, Myogenin, *MyoD*, *Igfbp5*, *Igf2*, and *Slug* by PAX3-FKHR transduction is demonstrated, as is the failure to induce these genes by PAX3. *Igf2* expression appears by Northern blotting to be suppressed by PAX3. Basal *c-Met* levels in NIH 3T3 cells transduced by the empty virus is high and remains high in the *Pax3* and PAX3-FKHR transduced clones. *Pdgfra* expression is repressed in the clones PF-1, PF-3, PAX3-C, and PAX3-1. (B) Myogenin protein expression is confirmed in the PAX3-FKHR transduced clones PF-C, PF-1, and PF-3 by Western analysis. (C) Northern blot analysis reveals expression of HSIX1, MYOG, IGFBP5, IGF2, *Slug*, and MERTK in several of the ARMS cell lines (RH3, RH4, RH5, RH28, and RH30). The first lane is normal muscle. A204 is an embryonal rhabdomyosarcoma that lacks the PAX3-FKHR chimeric oncogene.

oculis" (*so*) gene, which is expressed in the distal posterior and anterior limb regions of mouse embryos and is weakly expressed in skeletal muscles of the head and body during late development (22, 26). Of interest, *Six1* has recently been shown to activate the Myogenin promoter (27). When we investigated ARMS cells for the presence of HSIX1, we found high expression in all five of the ARMS cell lines tested, as predicted by our results in the NIH 3T3 model. However, HSIX1 expression has also been noted in other human cancers, and, of interest, over-expression in MCF-7 cells has been shown to abrogate the G2 cell cycle check-point (28).

We also confirmed expression in ARMS of another gene, *Slug*, as predicted by the NIH 3T3 model. *Slug* is a zinc finger transcription factor that has been related to neural crest (29) and limb bud development, where it may be involved in mesenchymal differentiation (30, 31). A third gene not previously related to ARMS, *IGFBP5*, was highly induced in all PAX3-FKHR transduced lines. It belongs to a family of secreted proteins that bind IGF1 and 2, thereby modulating their biological actions. It is known to be expressed in embryogenesis during muscle development (32) and is rapidly induced during terminal muscle differentiation of C21 myoblasts coincident with the onset of Myogenin gene expression (33). Indeed, we found that PF-1, the clone that expressed the highest level of Myogenin, also showed high levels of *Igfbp5*. Additionally, *IGFBP5* expression was observed in all five ARMS cell lines tested. Furthermore, *Igf2* itself was induced in PAX3-FKHR transduced cells. This growth factor, which modulates muscle growth and differentiation, is thought to be an autocrine growth and motility factor in ARMS, and its induction links PAX3-FKHR directly to an important mechanism of dysregulated growth and impaired differentiation (24, 34). Of interest, expression of *H19* (Table 1), which is closely

linked to *Igf2* in an imprinted region of mouse chromosome 7 (35), was also increased in the PAX3-FKHR-transduced cells.

Of the other possible PAX3 targets identified so far in the literature, including *GFAP*, *NGFR*, *N-CAM*, *L1* (36), and *c-Met* (21, 37), only *c-Met* was on our array, and it was not induced by PAX3-FKHR. However, Northern blot analysis revealed an already high basal expression level in NIH 3T3 cells that did not increase in cells transduced with *Pax3* or PAX3-FKHR (Fig. 4A), probably because of the high level of expression in the parental cells.

We noted that the genes that were strongly induced by PAX3-FKHR transduction were not induced or only weakly induced in *Pax3* transduced cells, despite the similar DNA binding specificity of these proteins. Even with comparable levels of expression of PAX3 and PAX3-FKHR, only PAX3-FKHR was able to induce the expression of a myogenic program including *MyoD* and Myogenin. This is in accord with the stronger transcriptional activity of PAX3-FKHR relative to PAX3, despite its reduced affinity for PAX3 targets previously reported and confirmed in our system (4). The increased transcriptional activity is most likely essential to the oncogenic properties of PAX3-FKHR and may be related to both gain of FKHR sequences and unresponsiveness to the transcriptional inhibitors of PAX3 (38).

Repression was not as prominent as induction in our study, with only four genes identified as repressed. It is also more difficult to interpret repression because the ability to measure this effect depends on initial gene expression levels in NIH 3T3 cells. Interestingly, although gene induction by PAX3 was not observed in our study, *Pax3*-transduced cells did exhibit repression of three of the four repressed genes identified. Decay accelerating factor (*Daf*) shows precisely the same reciprocal

relationship with another regulator of complement activity, Clusterin (Table 1), observed previously in myocytes (39). Another gene repressed in both *Pax3* and *PAX3-FKHR* transduced cells, *Pmx1*, is a mesoderm-specific paired box type homeodomain protein related to *Pax3*, which is highly expressed in adult skeletal muscle (40). Repression of *Pdgfra*, which is normally expressed in mouse mesodermal and neural-crest derived tissue, contrasts with the study of Epstein *et al.*, who demonstrated that PAX3-FKHR but not PAX3 can directly increase expression of *PDGFRA* (41). Their result was obtained in p19 embryonal carcinoma cells, which have an undetectable baseline level of *PDGFRA* expression. In contrast, NIH 3T3 cells have a high basal expression of *Pdgfra* and appear to respond to both PAX3 and PAX3-FKHR by repression of *Pdgfra* as confirmed by Northern blotting (Fig. 4A).

Although we have only sampled a portion of the murine genome in this study, the ability to assay parallel gene expression analysis provides a remarkable view of the myogenic gene expression program invoked by PAX3-FKHR in NIH 3T3 cells. In addition, our results correctly predicted the expression of *HSIX1*, *IGFBP5*, and *Slug* in ARMS. This study does not permit

us to distinguish direct from indirect targets of PAX3-FKHR. Resolving this issue and the complex interrelationships among the induced genes will require both alternative gene transfer technologies and other approaches, which are complementary to large-scale gene expression analysis. Our results lead us to speculate on certain aspects of the pathogenesis of ARMS. First, it is critical that the as-yet unidentified tumor progenitor cell must be competent to respond to the effects of PAX3-FKHR. Second, considering the profound myogenic effects of PAX3-FKHR, this cell may have the properties of a primitive muscle precursor, which on transformation by PAX3-FKHR, exhibits the muscle markers (such as Myogenin and *MYOD*) characteristic of ARMS. Failure of these abnormal rhabdomyoblasts to terminally differentiate and exit the cell cycle would permit expansion of this population of cells. The subsequent acquisition of secondary genetic alterations would then lead to the development of fully malignant ARMS.

We thank Kimberly A. Gayton, Alicia J. Faller, and Robert L. Walker for their excellent technical assistance.

- Barr, F. G. (1998) *Nat. Genet.* **19**, 121–124.
- Galili, N., Davis, R. J., Fredericks, W. J., Mukhopadhyay, S., Rauscher, F. J., III, Emanuel, B. S., Rovera, G. & Barr, F. G. (1993) *Nat. Genet.* **5**, 230–235.
- Shapiro, D. N., Sublett, J. E., Li, B., Downing, J. R. & Naeve, C. W. (1993) *Cancer Res.* **53**, 5108–5112.
- Fredericks, W. J., Galili, N., Mukhopadhyay, S., Rovera, G., Bannicelli, J., Barr, F. G. & Rauscher, F. J., III (1995) *Mol. Cell. Biol.* **15**, 1522–1535.
- Bannicelli, J. L., Fredericks, W. J., Wilson, R. B., Rauscher, F. J., III & Barr, F. G. (1995) *Oncogene* **11**, 119–130.
- Bober, E., Franz, T., Arnold, H. H., Gruss, P. & Tremblay, P. (1994) *Development (Cambridge, U.K.)* **120**, 603–612.
- Bannicelli, J. L., Edwards, R. H. & Barr, F. G. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 5455–5459.
- Davis, R. J. & Barr, F. G. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 8047–8051.
- Barr, F. G., Nauta, L. E., Davis, R. J., Schafer, B. W., Nycum, L. M. & Biegel, J. A. (1996) *Hum. Mol. Genet.* **5**, 15–21.
- Epstein, J. A., Lam, P., Jepeal, L., Maas, R. L. & Shapiro, D. N. (1995) *J. Biol. Chem.* **270**, 11719–11722.
- Scheidler, S., Fredericks, W. J., Rauscher, F. J., III, Barr, F. G. & Vogt, P. K. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 9805–9809.
- Lam, P. Y., Sublett, J. E., Hollenbach, A. D. & Roussel, M. F. (1999) *Mol. Cell. Biol.* **19**, 594–601.
- Miller, A. D. & Rosman, G. J. (1989) *BioTechniques* **7**, 980–2, 984–6, 989–990.
- Pear, W. S., Nolan, G. P., Scott, M. L. & Baltimore, D. (1993) *Proc. Natl. Acad. Sci. USA* **90**, 8392–8396.
- Khan, J., Simon, R., Bittner, M., Chen, Y., Leighton, S. B., Pohida, T., Smith, P. D., Jiang, Y., Gooden, G. C., Trent, J. M. & Meltzer, P. S. (1998) *Cancer Res.* **58**, 5009–5013.
- DeRisi, J., Penland, L., Brown, P. O., Bittner, M. L., Meltzer, P. S., Ray, M., Chen, Y., Su, Y. A. & Trent, J. M. (1996) *Nat. Genet.* **14**, 457–460.
- Shalon, D., Smith, S. J. & Brown, P. O. (1996) *Genome Res.* **6**, 639–645.
- Khan, J., Saal, L. H., Bittner, M. L., Chen, Y., Trent, J. M. & Meltzer, P. S. (1999) *Electrophoresis* **20**, 223–229.
- Chen, Y., Dougherty, E. R. & Bittner, M. L. (1997) *Biomed. Optics* **2**, 364–374.
- Graham, D. K., Bowman, G. W., Dawson, T. L., Stanford, W. L., Earp, H. S. & Snodgrass, H. R. (1995) *Oncogene* **10**, 2349–2359.
- Epstein, J. A., Shapiro, D. N., Cheng, J., Lam, P. Y. & Maas, R. L. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 4213–4218.
- Boucher, C. A., Carey, N., Edwards, Y. H., Siciliano, M. J. & Johnson, K. J. (1996) *Genomics* **33**, 140–142.
- Clark, J., Rocques, P. J., Braun, T., Bober, E., Arnold, H. H., Fisher, C., Fletcher, C., Brown, K., Gusterson, B. A., Carter, R. L., *et al.* (1991) *Br. J. Cancer* **64**, 1039–1042.
- El-Badry, O. M., Minniti, C., Kohn, E. C., Houghton, P. J., Daughaday, W. H. & Helman, L. J. (1990) *Cell Growth Differ.* **1**, 325–331.
- Strohman, R. C., Micou-Eastwood, J., Glass, C. A. & Matsuda, R. (1983) *Science* **221**, 955–957.
- Oliver, G., Wehr, R., Jenkins, N. A., Copeland, N. G., Cheyette, B. N., Hartenstein, V., Zipursky, S. L. & Gruss, P. (1995) *Development (Cambridge, U.K.)* **121**, 693–705.
- Spitz, F., Demignon, J., Porteu, A., Kahn, A., Concordet, J. P., Daegelen, D. & Maire, P. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 14220–14225.
- Ford, H. L., Kabingu, E. N., Bump, E. A., Mutter, G. L. & Pardee, A. B. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 12608–12613.
- Nieto, M. A., Sargent, M. G., Wilkinson, D. G. & Cooke, J. (1994) *Science* **264**, 835–839.
- Cohen, M. E., Yin, M., Paznekas, W. A., Schertzer, M., Wood, S. & Jabs, E. W. (1998) *Genomics* **51**, 468–471.
- Buxton, P. G., Kostakopoulou, K., Brickell, P., Thorogood, P. & Ferretti, P. (1997) *Int. J. Dev. Biol.* **41**, 559–568.
- Green, B. N., Jones, S. B., Streck, R. D., Wood, T. L., Rotwein, P. & Pintar, J. E. (1994) *Endocrinology* **134**, 954–962.
- Rotwein, P., James, P. L. & Kou, K. (1995) *Mol. Endocrinol.* **9**, 913–923.
- Wang, W., Kumar, P., Epstein, J., Helman, L., Moore, J. V. & Kumar, S. (1998) *Cancer Res.* **58**, 4426–4433.
- Bartolomei, M. S., Zemel, S. & Tilghman, S. M. (1991) *Nature (London)* **351**, 153–155.
- Kioussi, C., Gross, M. K. & Gruss, P. (1995) *Neuron* **15**, 553–562.
- Ginsberg, J. P., Davis, R. J., Bannicelli, J. L., Nauta, L. E. & Barr, F. G. (1998) *Cancer Res.* **58**, 3542–3546.
- Hollenbach, A. D., Sublett, J. E., McPherson, C. J. & Grosveld, G. (1999) *EMBO J.* **18**, 3702–3711.
- Gasque, P., Morgan, B. P., Legoudec, J., Chan, P. & Fontaine, M. (1996) *J. Immunol.* **156**, 3402–3411.
- Cserjesi, P., Lilly, B., Brynson, L., Wang, Y., Sassoon, D. A. & Olson, E. N. (1992) *Development (Cambridge, U.K.)* **115**, 1087–1101.
- Epstein, J. A., Song, B., Lakkis, M. & Wang, C. (1998) *Mol. Cell. Biol.* **18**, 4118–4130.
- Schafer, B. W., Czerny, T., Bernasconi, M., Genini, M. & Busslinger, M. (1994) *Nucleic Acids Res.* **22**, 4574–4582.